CytoDyn to Hold Webcast on October 20 to Discuss DSMC’s Recommendations from the Interim Analysis of the Phase 2b/3 Clinical Trial for Severe-to-Critical COVID-19 Patients

Rhea-AI Summary

CytoDyn Inc. (OTC.QB: CYDY) announced an upcoming investment community webcast on October 20, 2020, to discuss recommendations from the Data Safety Monitoring Committee (DSMC) based on an interim analysis of the Phase 2b/3 trial for severe-to-critical COVID-19. Key management, including President Nader Pourhassan, will provide insights into a potential regulatory path forward. The webcast will feature a presentation followed by a Q&A session. Access will be through CytoDyn's corporate website, with replay available for 30 days.

Positive

• Management is hosting a webcast to discuss interim findings from the clinical trial.
• Potential regulatory path forward for leronlimab based on DSMC recommendations.

Negative

• None.

VANCOUVER, Washington, Oct. 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Jacob Lalezari, M.D., Senior Science Advisor, will host an investment community webcast on Tuesday, October 20, 2020.

Management will discuss the recommendations of the Data Safety Monitoring Committee (DSMC) following their review of the interim analysis of the first 195 patients enrolled in the Company’s Phase 2b/3 clinical trial for patients with severe-to-critical COVID-19 indications, including a potential regulatory path forward.

Management will also present slides during the webcast followed by approximately 30-45 minutes to address questions submitted online by analysts and investors.

Date: Tuesday, October 20, 2020
Time: 1:00 pm PT / 4:00 pm ET
Dial-In: None.
Questions: Can be submitted online through the link noted below.

This is a “listen only” webcast, which can be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days. Participants are encouraged to go to the website 15 minutes prior to the start of the webcast to register, download and install any necessary software. The webcast can also be accessed via the following link:

https://78449.themediaframe.com/dataconf/productusers/cydy/mediaframe/41443/indexl.html

The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until November 20, 2020.

CONTACTS
Investors:
Michael Mulholland
Office: 360.980.8524, ext. 102
mmulholland@cytodyn.com

FAQ

What is the purpose of the CytoDyn webcast on October 20, 2020?

The webcast aims to discuss the recommendations from the DSMC regarding the Phase 2b/3 clinical trial for COVID-19 and potential regulatory pathways.

Who will speak during the CytoDyn investment community webcast?

Key management including Nader Pourhassan, Scott Kelly, and Jacob Lalezari will present during the webcast.

How can I access the CytoDyn webcast?

The webcast can be accessed via CytoDyn's corporate website under the Investors section.

What is the significance of the DSMC recommendations for CytoDyn?

The DSMC recommendations are crucial as they may outline the potential regulatory strategy for advancing leronlimab for COVID-19 treatment.

Will the CytoDyn webcast be recorded for later access?

Yes, the webcast will be archived and available for replay for 30 days after the event.